GT Medical Technologies (GT) is a commercial stage, US-based medical device company that specializes in developing innovative products for the treatment of brain tumors.

GT has created a product called GammaTile Therapy, which is an implantable radiation therapy for the treatment of brain tumors – a novel approach delivering a targeted dose of radiation directly to the tumor site while minimizing damage to surrounding healthy tissue. Compared to the current standard of care, it provides solutions for immediate radiation therapy, with limited to no side effects, and 100% patient compliance. These benefits are being studied to evaluate the extension and quality of life for brain tumor patients. The company has received FDA clearance for the use of GammaTile Therapy in patients with newly diagnosed malignant brain tumors and recurrent brain tumors.

Gilde Healthcare invested in GT in 2023 to support the company’s continued commercial expansion, clinical evidence generation, and further product innovation to help the business advance the field of neuro-oncology and improve the lives of patients with brain tumors.